Exact Mass: 418.2620144
Exact Mass Matches: 418.2620144
Found 500 metabolites which its exact mass value is equals to given mass value 418.2620144,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
4,4-(Diphenylethenylidene)bis[N,N-dimethylbenzenamine]
Simvastatin
C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3144 CONFIDENCE standard compound; INTERNAL_ID 1128
3alpha,12alpha-Dihydroxy-5beta-pregnan-20-one diacetate
Simvastatin
Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels.; Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. [HMDB] Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels. Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Simvastatin. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=79902-63-9 (retrieved 2024-10-09) (CAS RN: 79902-63-9). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
Cavipetin D
Cavipetin D is found in mushrooms. Cavipetin D is a constituent of the edible mushroom (Boletinus cavipes) Constituent of the edible mushroom (Boletinus cavipes). Cavipetin D is found in mushrooms.
CPA(18:1(11Z)/0:0)
cPA(18:1(11Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:1(11Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.
CPA(18:1(9Z)/0:0)
cPA(18:1(9Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis. [HMDB] cPA(18:1(9Z)/0:0) is a cyclic phosphatidic acid or cyclic lysophosphatidic acid. It is a glycerophospholipid in which a cyclic phosphate moiety occupies two glycerol substitution sites. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1). Fatty acids containing 16 and 18 carbons are the most common. Cyclic phosphatidic acids have been detected in a wide range of organisms including humans, especially in the brain but also in serum (at a concentration of 10-7M). cPAs have a cyclic phosphate at the sn-2 and sn-3 positions of the glycerol carbons, and this structure is absolutely necessary for their activities. In particular, it is found in tissues subject to injury, and while it may have some similar signalling functions to lysophosphatidic acid per se, it also has some quite distinct biological activities. For example, cyclic phosphatidic acid is known to be a specific inhibitor of DNA polymerase alpha. It has an appreciable effect on the inhibition of cancer cell invasion and metastasis.
N-Arachidonoyl Asparagine
N-arachidonoyl asparagine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Arachidonic acid amide of Asparagine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Arachidonoyl Asparagine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Arachidonoyl Asparagine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Palosuran
C25H30N4O2 (418.23686399999997)
(1R,3S,7R,8R,8As)-8-{2-[(2R,4S)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
Simvastatin is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; Simvastatin is a powerful lipid-lowering drug that can decrease low density lipoprotein (LDL) levels by up to 50 percent. It is used in doses of 5 mg up to 80 mg. Higher doses (160 mg) have been found to be too toxic, while giving only minimal benefit in terms of lipid lowering. There is no real effect on HDL and triglyceride levels.; Simvastatin (INN) is a hypolipidemic drug belonging to the class of pharmaceuticals called statins. It is used to control hypercholesterolemia (elevated cholesterol levels) and to prevent cardiovascular disease. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus; The drug is the form of an inactive lactone that is hydrolized after ingestion to produce the active agent. It is a white, nonhygroscopic, crystalline powder that is practically insoluble in water, and freely soluble in chloroform, methanol and ethanol; Ezetimibe/simvastatin is a combination product to lower lipids and marketed as Vytorin. [HMDB]
Valbenazine
MG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0/0:0)
MG(22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0/0:0)
MG(22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0/0:0)
MG(22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0/0:0)
MG(22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0/0:0)
MG(22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0)
MG(0:0/22:6(5Z,7Z,10Z,13Z,16Z,19Z)-OH(4)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0)
MG(0:0/22:6(4Z,8Z,10Z,13Z,16Z,19Z)-OH(7)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0)
MG(0:0/22:6(4Z,7Z,10Z,12E,16Z,19Z)-OH(14)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0)
MG(0:0/22:6(4Z,7Z,10Z,13E,15E,19Z)-OH(17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0)
MG(0:0/22:5(4Z,7Z,10Z,13Z,19Z)-O(16,17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MFA
Mfa is practically insoluble (in water) and an extremely weak acidic compound (based on its pKa). Mfa can be found in french plantain, which makes mfa a potential biomarker for the consumption of this food product. MFA may refer to: .
Ophiopogonoside A
Ophiopogonoside A is a natural product found in Ophiopogon japonicus and Liriope muscari with data available.
3alpha-Angeloyloxy-18-hydroxy-ent-labd-8(17)-13E-dien-15-oic acid
6alpha-Angeloyloxy-7-oxo-13,14-dihydrokolavenic acid
Aplysinoplide B
A sesterterpenoid isolated from the marine sponge Aplysinopsis digitata that exhibits cytotoxicity against P388 mouse leukemia cells.
12beta,16alpha,20-Trihydroxy-17-scalaren-19,20-olide
19-(Dimethylarsinoyl)nonadecanoic acid
C21H43AsO3 (418.24279879999995)
(1R,4R,5R,7R,10S)-10,11,15-trihydroxyguaiane 11-O-beta-D-glucopyranoside
6alpha,15(S),23-trihydroxy-labd-8(22),13(14),17-trien-16(S),19-olide
8alpha,15(S)-dihydroxy-23,6alpha-epoxy-labd-13(14),17-dien-16(S),19-olide
Di-Ac-(3beta,5alpha,6alpha)-3,6-Dihydroxypregnan-20-one
6alpha,8alpha,23-trihydroxy-labd-13(14),15,17-trien-16,19-olide
Di-Ac-(3beta,5alpha,16alpha)-3,16-Dihydroxypregnan-20-one
(2E,4E,6E)-cyclo-[(NMe-L-Ala)-L-Val-(Nalpha-octa-2,4,6-trienoyl-L-Orn)]|sclerotiotide A
C22H34N4O4 (418.25799240000003)
celerioside E|eudesmane-1beta,4alpha,11-triol 11-O-beta-D-glucopyranoside
3alpha-angeloyloxy-2alpha-hydroxy-13,14Z-dehydrocativic acid
6alpha,8alpha-dihydroxy-23-oxo-labd-13(14),17-dien-16(R),19-olide
Di-Ac-(3beta,5beta,17alphaOH)-3,17-Dihydroxypregnan-20-one
19-dimethylarsinoyl-nonadecanoic acid
C21H43AsO3 (418.24279879999995)
9beta-acetoxy-13alpha-hydroxy-3beta-propionoxy-1beta,8beta-trinervita-11,15(17)-diene
2-Acetoxy-5-methoxy-6-methyl-3-[(Z-10-pentadecenyl)-1,4-benzoquinone]
eudesman-3,4alpha,11-triol-11-O-beta-D-glucopyranoside
ent-17-Succinyloxy-15alpha,16alpha-epoxybeyeran-methylester
ent-19-Succinyloxy-15alpha,16alpha-epoxybeyeran-methylester
18-oxo-19-senecioyloxy-ent-clerod-3-en-15-oic acid
3-Ketone,2-(3-methyl-2-butenoyl)----2,3,16,17-Phyllocladanetetrol
2-Methoxy-5-acetoxy-6-methyl-3-[(z)-10-pentadecenyl]-1,4-benzoquinone
(2E,6E)-10-beta-D-glucopyranosyl-1,10,11-trihydroxy-3,7,11-trimethyldodeca-2,6-diene
3-(3-Methylbutanoyl)-(ent-3beta)-3, 9-Dihydroxy-15-kauren-19-oic acid
C22H34N4O4_N-Methyl-N-[(2E,4E,6E)-2,4,6-octatrienoyl]valylalanylprolinamide
C22H34N4O4 (418.25799240000003)
Gly Lys Lys Ser
Gly Lys Ser Lys
Gly Ser Lys Lys
Ile Ile Ser Ser
Ile Leu Ser Ser
Ile Ser Ile Ser
Ile Ser Leu Ser
Ile Ser Ser Ile
Ile Ser Ser Leu
Ile Ser Thr Val
Ile Ser Val Thr
Ile Thr Ser Val
Ile Thr Val Ser
Ile Val Ser Thr
Ile Val Thr Ser
Lys Gly Lys Ser
Lys Gly Ser Lys
Lys Lys Gly Ser
Lys Lys Ser Gly
Lys Ser Gly Lys
Lys Ser Lys Gly
Leu Ile Ser Ser
Leu Leu Ser Ser
Leu Ser Ile Ser
Leu Ser Leu Ser
Leu Ser Ser Ile
Leu Ser Ser Leu
Leu Ser Thr Val
Leu Ser Val Thr
Leu Thr Ser Val
Leu Thr Val Ser
Leu Val Ser Thr
Leu Val Thr Ser
Ser Gly Lys Lys
Ser Ile Ile Ser
Ser Ile Leu Ser
Ser Ile Ser Ile
Ser Ile Ser Leu
Ser Ile Thr Val
Ser Ile Val Thr
Ser Lys Gly Lys
Ser Lys Lys Gly
Ser Leu Ile Ser
Ser Leu Leu Ser
Ser Leu Ser Ile
Ser Leu Ser Leu
Ser Leu Thr Val
Ser Leu Val Thr
Ser Ser Ile Ile
Ser Ser Ile Leu
Ser Ser Leu Ile
Ser Ser Leu Leu
Ser Thr Ile Val
Ser Thr Leu Val
Ser Thr Val Ile
Ser Thr Val Leu
Ser Val Ile Thr
Ser Val Leu Thr
Ser Val Thr Ile
Ser Val Thr Leu
Thr Ile Ser Val
Thr Ile Val Ser
Thr Leu Ser Val
Thr Leu Val Ser
Thr Ser Ile Val
Thr Ser Leu Val
Thr Ser Val Ile
Thr Ser Val Leu
Thr Thr Val Val
Thr Val Ile Ser
Thr Val Leu Ser
Thr Val Ser Ile
Thr Val Ser Leu
Thr Val Thr Val
Thr Val Val Thr
Val Ile Ser Thr
Val Ile Thr Ser
Val Leu Ser Thr
Val Leu Thr Ser
Val Ser Ile Thr
Val Ser Leu Thr
Val Ser Thr Ile
Val Ser Thr Leu
Val Thr Ile Ser
Val Thr Leu Ser
Val Thr Ser Ile
Val Thr Ser Leu
Val Thr Thr Val
Val Thr Val Thr
Val Val Thr Thr
Cavipetin D
4-[(3,4-dimethylbenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
sodium 2,3-bis[(2-ethylhexyl)oxy]propyl sulphate
C19H39NaO6S (418.23649140000003)
6-((3-((tert-Butyldimethylsilyloxy)methyl)pyrrolidin-1-yl)methyl)-2-(trimethylsilyl)furo[3,2-b]pyrid
C22H38N2O2Si2 (418.24716879999994)
sodium 2-[(2-ethylhexyl)oxy]-1-[[(2-ethylhexyl)oxy]methyl]ethyl sulphate
C19H39NaO6S (418.23649140000003)
tert-butyl 4-((4-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazine-1-carboxylate
N-(1-adamantylmethyl)-2-chloro-5-[3-(3-hydroxypropylamino)propyl]benzamide
Bunamidine Hydrochloride
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent
Palosuran
C25H30N4O2 (418.23686399999997)
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
3-(2-Amino-6-Benzoylquinazolin-3(4h)-Yl)-N-Cyclohexyl-N-Methylpropanamide
C25H30N4O2 (418.23686399999997)
1-{7-Cyclohexyl-6-[4-(4-Methylpiperazin-1-Yl)benzyl]-7h-Pyrrolo[2,3-D]pyrimidin-2-Yl}methanamine
1-(9Z,12Z)-octadecadienylglycerone 3-phosphate
A 1-alkylglycerone 3-phosphate in which the alkyl group is specified as (9Z,12Z)-octadecadienyl.
N-(5-{3-[(5-Amino-pentyl)-hydroxy-carbamoyl]-propionylamino}-pentyl)-N-hydroxy-succinamic acid
[3-Carboxy-2-(13-carboxy-4-hydroxytridecanoyl)oxypropyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
[3-Carboxy-2-(13-carboxy-6-hydroxytridecanoyl)oxypropyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
[3-Carboxy-2-(13-carboxy-7-hydroxytridecanoyl)oxypropyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
[3-Carboxy-2-(13-carboxy-5-hydroxytridecanoyl)oxypropyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
[3-Carboxy-2-(13-carboxy-3-hydroxytridecanoyl)oxypropyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
6-(4-Benzoyl-1-piperazinyl)-3,3-dimethyl-8-propan-2-yl-1,4-dihydropyrano[3,4-c]pyridine-5-carbonitrile
C25H30N4O2 (418.23686399999997)
N-{3-cyano-4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl}cyclohexanecarboxamide
C25H30N4O2 (418.23686399999997)
2-cyclopropyl-1-[(2R,3R)-2-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyrimidin-5-ylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
C25H30N4O2 (418.23686399999997)
2-cyclopropyl-1-[(2S,3S)-2-(hydroxymethyl)-3-[4-[(E)-prop-1-enyl]phenyl]-1-(pyrimidin-5-ylmethyl)-1,6-diazaspiro[3.3]heptan-6-yl]ethanone
C25H30N4O2 (418.23686399999997)
2,2-dimethylbutanoic acid [(7S,8S)-8-[2-[(2R)-4-hydroxy-6-oxo-2-oxanyl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] ester
[(1S,3R,7S,8R,8aS)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
[(1R,3R,7S,8R,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
(1-butanoyloxy-3-hydroxypropan-2-yl) (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
(1-acetyloxy-3-hydroxypropan-2-yl) (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
[1-Carboxy-3-(2-octanoyloxy-3-propanoyloxypropoxy)propyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
[3-(3-Butanoyloxy-2-heptanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
[3-(3-Acetyloxy-2-nonanoyloxypropoxy)-1-carboxypropyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
[1-Carboxy-3-(2-hexanoyloxy-3-pentanoyloxypropoxy)propyl]-trimethylazanium
C21H40NO7+ (418.28046300000005)
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
(2-hydroxy-2-oxo-1,3,2$l^{5}-dioxaphospholan-4-yl)methyl (9Z)-octadec-9-enoate
(2-hydroxy-2-oxo-1,3,2$l^{5}-dioxaphospholan-4-yl)methyl (11Z)-octadec-11-enoate
1-oleoyl-sn-glycerol 2,3-cyclic phosphate
A 1-acyl-sn-glycerol 2,3-cyclic phosphate having oleoyl as the 1-O-acyl group.
3beta-hydroxy-5beta-pregnan-20-one hemisuccinate
A sterol ester that is the O-succinoyl derivative of 3beta-hydroxy-5beta-pregnan-20-one.
1-Oleylglycerone 3-phosphate(2-)
A 1-alkylglycerone 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-oleylglycerone 3-phosphate; major species at pH 7.3.
3beta-hydroxy-5alpha-pregnan-20-one hemisuccinate
A sterol ester that is the O-succinoyl derivative of 3beta-hydroxy-5alpha-pregnan-20-one.
2-[(5,8-dihydroxy-2-isopropyl-4a,8-dimethyl-octahydronaphthalen-1-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,3s,4r,7r,8e,11s,12r)-12-[(2s,3z,5s)-5,6-dihydroxy-6-methylhept-3-en-2-yl]-4-hydroxy-1,4-dimethyl-6-oxotricyclo[9.3.0.0³,⁷]tetradec-8-ene-8-carbaldehyde
(10e,14e)-17-[(2s)-2-hydroxy-5-oxo-2h-furan-3-yl]-6,6,10,14-tetramethylheptadeca-10,14-diene-2,7-dione
n-(2,8-dihydroxy-6-isopropyl-3,4-dimethyl-5-oxo-1,4,7-triazacyclododeca-1,7-dien-9-yl)octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
8-(acetyloxy)-1-ethyl-9a,11a-dimethyl-2-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
3-hydroxy-3-isopropyl-6,8a-dimethyl-4-[(2-methylbut-2-enoyl)oxy]-1,2,3a,4,5,8-hexahydroazulen-1-yl 2-methylbut-2-enoate
(5z)-5-[(2s)-2-[(3r,4ar,6s,6as,10as,10br)-6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl]-2-hydroxyethylidene]-4-methylfuran-2-one
3-ethenyl-10-hydroxy-3,4a,7,7,10a-pentamethyl-5-oxo-octahydronaphtho[2,1-b]pyran-8-yl 2-methylbut-2-enoate
2-{[1-hydroxy-1-(hydroxymethyl)-5-isopropyl-7a-methyl-hexahydro-2h-inden-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(3ar,7s,16as)-2,7-dihydroxy-10-(hydroxymethyl)-3-[(2s)-1-hydroxypropan-2-yl]-6,14,16a-trimethyl-3ah,4h,7h,8h,9h,12h,13h,16h-cyclopenta[15]annulen-1-one
(2e,4e,6z)-n-[(3s,6s,9s)-2,5-dihydroxy-6-isopropyl-3,7-dimethyl-8-oxo-1,4,7-triazacyclododeca-1,4-dien-9-yl]octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
(2s,3r,4s,5s,6r)-2-{[(3s,6e,10s)-10,11-dihydroxy-3,7,11-trimethyldodeca-1,6-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
n-({[(2r,4ar,7s,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy}(hydroxy)methylidene)-2-hydroxyethanecarbamimidic acid
4-[(16-hydroxy-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)oxy]-3-methyl-4-oxobut-2-enoic acid
(4r,5as,5br,7as,11as,11br,13r,13as)-1,4,13-trihydroxy-5b,8,8,11a,13a-pentamethyl-1h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-3-one
(5r)-4-[(1r,3e)-1,5-dihydroxy-4-[(3e)-4-methyl-6-(2,6,6-trimethylcyclohex-1-en-1-yl)hex-3-en-1-yl]pent-3-en-1-yl]-5-hydroxy-5h-furan-2-one
(5s)-5-[(1e)-2-[(3r,4ar,6s,6as,10as,10br)-6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl]ethenyl]-5-hydroxy-4-methylfuran-2-one
(5s)-4-[(1r,3e)-1,5-dihydroxy-4-[(3e)-4-methyl-6-(2,6,6-trimethylcyclohex-1-en-1-yl)hex-3-en-1-yl]pent-3-en-1-yl]-5-hydroxy-5h-furan-2-one
(2s,3r,4s,5s,6r)-2-{[(3s,6e,10e)-2,12-dihydroxy-2,6,10-trimethyldodeca-6,10-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,7r,8s,9as,11as)-8-(acetyloxy)-1-ethyl-9a,11a-dimethyl-2-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
2-acetoxy-5-methoxy-6-methyl-3-[(z-10'-pentadecenyl)-1,4-benzoquinone]
{"Ingredient_id": "HBIN005110","Ingredient_name": "2-acetoxy-5-methoxy-6-methyl-3-[(z-10'-pentadecenyl)-1,4-benzoquinone]","Alias": "NA","Ingredient_formula": "C25H38O5","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "253","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-methoxy-5-acetoxy-6-methyl-3-[(z)-10'-pentadecenyl]-1,4-benzoquinone
{"Ingredient_id": "HBIN005897","Ingredient_name": "2-methoxy-5-acetoxy-6-methyl-3-[(z)-10'-pentadecenyl]-1,4-benzoquinone","Alias": "NA","Ingredient_formula": "C25H38O5","Ingredient_Smile": "CCCCC=CCCCCCCCCCC1=C(C(=O)C(=C(C1=O)OC(=O)C)C)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "13822","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
Bakkenolidc-K
{"Ingredient_id": "HBIN017533","Ingredient_name": "Bakkenolidc-K","Alias": "NA","Ingredient_formula": "C24H34O6","Ingredient_Smile": "CC=C(C)C(=O)OC1C2C(CCC(C2(CC13C(=C)COC3=O)C)C)OC(=O)C(C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "35675","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-[(2,12-dihydroxy-2,6,10-trimethyldodeca-6,10-dien-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
[(1s,4s,4as,5r,7s,8r,8ar)-1,4,5,8-tetrahydroxy-7-isopropyl-4a-methyl-octahydronaphthalen-1-yl]methyl (2e)-3-phenylprop-2-enoate
4-({4-[2-(furan-3-yl)ethyl]-3-(hydroxymethyl)-4,8,8a-trimethyl-1,2,3,4a,5,6-hexahydronaphthalen-2-yl}oxy)-4-oxobutanoic acid
(1r,2r,4r,8r,9r,10s,13s,16r)-8-(acetyloxy)-2-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-16-yl acetate
(1s,4r,7r,9r,10s,13r,14r)-14-hydroxy-14-(hydroxymethyl)-5,5,9-trimethyl-6-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-7-yl 3-methylbut-2-enoate
(1r)-1-[(1r,4s,6r,10r,11r)-11-(acetyloxy)-4-methyl-9-methylidene-5,12-dioxatricyclo[8.4.0.0⁴,⁶]tetradec-13-en-14-yl]-4-methylpent-3-en-1-yl acetate
7,7a-dimethyl-4'-methylidene-4-[(2-methylpropanoyl)oxy]-2'-oxo-hexahydro-1h-spiro[indene-2,3'-oxolan]-3-yl 3-methylbut-2-enoate
(2s,3r,4s,5s,6r)-2-{[(3s,6e,10s)-3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
2-{2-hydroxy-4,8-dimethyl-10-[(2-methylbut-2-enoyl)oxy]cyclodeca-3,7-dien-1-yl}propyl 2-methylbut-2-enoate
{2,5-dihydroxy-6-[(2e,4e,6e)-1-hydroxy-3,7,11-trimethyldodeca-2,4,6,10-tetraen-1-yl]-7-oxabicyclo[4.1.0]hept-3-en-3-yl}methyl acetate
(1r,3as,4r,8s,8as)-1-hydroxy-1-isopropyl-3a,6-dimethyl-8-{[(2z)-2-methylbut-2-enoyl]oxy}-2,3,4,7,8,8a-hexahydroazulen-4-yl (2z)-2-methylbut-2-enoate
(2z)-5-[(1s,4ar,6s,7r,8ar)-7-hydroxy-2,5,5,8a-tetramethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-2-enoic acid
(1s,3r,3as,4s,8ar)-3-hydroxy-3-isopropyl-6,8a-dimethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-1,2,3a,4,5,8-hexahydroazulen-1-yl (2z)-2-methylbut-2-enoate
4-[(3e,7e)-10-[(1s,5s)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
5-(4-hydroxy-4-methylpent-2-en-1-yl)-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
(1r,2r,6r)-6-[(2e,6e,10e)-12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-3-(hydroxymethyl)-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl acetate
(2r,3r,4r,5r)-4-{[(3r,4ar,5s,8as)-3-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methoxy}hexane-1,2,3,5,6-pentol
7,7a-dimethyl-4'-methylidene-4-[(2-methylpropanoyl)oxy]-2'-oxo-hexahydro-1h-spiro[indene-2,3'-oxolan]-3-yl 2-methylbut-2-enoate
(1r,2r,4r,7s,9r,10e,13r,15s,16s)-16-(acetyloxy)-4,8,8,11,15-pentamethyl-12-oxo-3-oxatetracyclo[11.3.0.0²,⁴.0⁷,⁹]hexadec-10-en-13-yl acetate
[2,5-dihydroxy-6-(1-hydroxy-3,7,11-trimethyldodeca-2,4,6,10-tetraen-1-yl)-7-oxabicyclo[4.1.0]hept-3-en-3-yl]methyl acetate
5-[(1r,3as,3bs,4s,5as,7s,9as,9bs,11s,11as)-3a,4,7,11-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]pyran-2-one
(2s,3r,4s,5s,6r)-2-{[(1s,4s,4as,7s,8as)-4-hydroxy-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
14-hydroxy-14-(hydroxymethyl)-5,5,9-trimethyl-6-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-7-yl 3-methylbut-2-enoate
[5-hydroxy-6-(1-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]methyl acetate
(1s,2e,5r,9s,11e,15s,16r)-7,15-dihydroxy-6-[(2s)-1-hydroxypropan-2-yl]-2,9,12,16-tetramethyl-19-oxatricyclo[14.2.1.0⁵,⁹]nonadeca-2,6,11-trien-8-one
(3r)-5-[(1s,2s,4r,4ar,8ar)-1,2,4a,5-tetramethyl-4-{[(2z)-2-methylbut-2-enoyl]oxy}-3-oxo-4,7,8,8a-tetrahydro-2h-naphthalen-1-yl]-3-methylpentanoic acid
(3r,4s,5r,6s,7s,11r,12s,13r,14r)-14-ethyl-4,6,9,12-tetrahydroxy-9-(hydroxymethyl)-3,5,7,11,13-pentamethyl-1-oxacyclotetradecane-2,10-dione
5-{7-hydroxy-2,5,5,8a-tetramethyl-6-[(2-methylbut-2-enoyl)oxy]-1,4,4a,6,7,8-hexahydronaphthalen-1-yl}-3-methylpent-2-enoic acid
[(1as,1bs,3r,3ar,5s,7br,9r,9ar)-9-(acetyloxy)-3-hydroxy-5,7b-dimethyl-5-[(2s)-oxiran-2-yl]-1h,1bh,2h,3h,3ah,4h,6h,8h,9h,9ah-cyclopropa[a]phenanthren-1a-yl]methyl acetate
[(1s,2s,3r,4ar,6r,8as)-3-(acetyloxy)-1-[2-(furan-3-yl)ethyl]-6-hydroxy-2,4a-dimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl acetate
[(1r,2s,4s,5s,9r,10s,11r,13r)-11-(acetyloxy)-2-hydroxy-5,9-dimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methyl acetate
(2e,4e,6e)-n-[(3s,6s,9s)-2,5-dihydroxy-6-isopropyl-3,7-dimethyl-8-oxo-1,4,7-triazacyclododeca-1,4-dien-9-yl]octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
(1s,2s,3e,5r,7e,11r)-5-[(3r)-3-hydroxy-4-methylpent-4-en-1-yl]-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
[(1r,2s,3s,8ar,10ar)-2-(acetyloxy)-3-hydroxy-1-isopropyl-8a,10a-dimethyl-6-oxo-1h,2h,3h,7h,8h,9h,10h-cyclohexa[f]azulen-5-yl]methyl acetate
4-[(7e)-10-[(1s,5s)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
(2r,3r,4s,5s,6r)-2-{[(3s,6e,10s)-10,11-dihydroxy-3,7,11-trimethyldodeca-1,6-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,2r)-6-[(2e,6e,10e)-12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-3-(hydroxymethyl)-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl acetate
n-(2-{3'-[2-(dimethylamino)ethyl]-5'-hydroxy-1'h-[1,4'-biindol]-3-yl}ethyl)-n-methylacetamide
C25H30N4O2 (418.23686399999997)
(1r,4s,5as,5br,7as,11as,11br,13r,13as)-1,4,13-trihydroxy-5b,8,8,11a,13a-pentamethyl-1h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-3-one
(3e,5e,7e,10s,12r,14e,16e,18e,20s,22s)-10,12,20-trihydroxy-22-[(2r)-2-hydroxypropyl]-1-oxacyclodocosa-3,5,7,14,16,18-hexaen-2-one
8-(acetyloxy)-16-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-2-yl acetate
(1r,2s,4r,5r,6r,9r,12s)-12-(acetyloxy)-5-isopropyl-6,9-dimethyl-3-oxo-15-oxatetracyclo[7.6.1.0²,⁶.0¹³,¹⁶]hexadec-13(16)-en-4-yl acetate
[5-(acetyloxy)-4-(hydroxymethyl)-7,11b-dimethyl-1h,2h,3h,4ah,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-4-yl]methyl acetate
(1r,4as,5r,6r,8ar)-6-hydroxy-1,4a,6-trimethyl-5-[(3e)-3-methyl-5-[(2r)-3-methyl-5-oxo-2h-furan-2-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalene-1-carboxylic acid
1-[1-({7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl}-c-hydroxycarbonimidoyl)-1-methylethyl]-5-oxopyrrolidine-2-carboxylic acid
(2r)-2-[(2r)-4-[(3s)-3,7-dimethylocta-1,6-dien-3-yl]-2-[(1e)-2-methoxyethenyl]-5-oxofuran-2-yl]-2-hydroxyethyl (2z)-2-methylbut-2-enoate
(1s,5r,9r)-1-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-5,9-dihydroxy-6-(hydroxymethyl)-2-oxabicyclo[3.3.1]non-6-ene-3,8-dione
(2r,3s,4s,5s,6s)-2-{[(1r,2s,4ar,5r,8s,8ar)-5,8-dihydroxy-2-isopropyl-4a,8-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,3as,3br,5as,7r,8s,9as,9bs,11as)-8-(acetyloxy)-1-ethyl-9a,11a-dimethyl-2-oxo-tetradecahydrocyclopenta[a]phenanthren-7-yl acetate
[(1s,2r,4s,4ar,8ar)-4-(acetyloxy)-1,2-dimethyl-5-methylidene-1-[2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-2h-naphthalen-4a-yl]methyl acetate
(3e,5e,7e,14e,16e,18e)-10,12,20-trihydroxy-22-(2-hydroxypropyl)-1-oxacyclodocosa-3,5,7,14,16,18-hexaen-2-one
10-hydroxy-5,9,14-trimethyl-6-[(3-methylbutanoyl)oxy]tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-5-carboxylic acid
5,7-dimethoxy-3-(6-{7-methyl-1,6-dioxaspiro[4.4]nonan-2-yl}hexyl)-3h-2-benzofuran-1-one
12-(acetyloxy)-5-isopropyl-6,9-dimethyl-3-oxo-15-oxatetracyclo[7.6.1.0²,⁶.0¹³,¹⁶]hexadec-13(16)-en-4-yl acetate
3-[5-(2-{1a,5,6-trimethyl-octahydrocyclopropa[e]naphthalen-5-yl}ethyl)-2-hydroxy-3,6-dihydropyran-2-yl]-4-oxobutanoic acid
[(1r,2r,6r)-2-hydroxy-6-[(2e,6e,10e)-12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]methyl acetate
(1r,4ar,5r,6r,8ar)-6-hydroxy-1,4a,6-trimethyl-5-[(3e)-3-methyl-5-[(2r)-3-methyl-5-oxo-2h-furan-2-yl]pent-3-en-1-yl]-hexahydro-2h-naphthalene-1-carboxylic acid
1-[(1r,4as,7r,8as,9s,10ar)-7-ethenyl-9-hydroxy-1,4a,7-trimethyl-8-oxo-2,3,4,6,8a,9,10,10a-octahydrophenanthren-1-yl]methyl 3-methyl propanedioate
7,7a-dimethyl-4'-methylidene-3-[(2-methylpropanoyl)oxy]-2'-oxo-hexahydro-1h-spiro[indene-2,3'-oxolan]-4-yl 3-methylbut-2-enoate
13,19,21-trihydroxy-5-methyl-6,25-dioxabicyclo[22.1.0]pentacosa-8,10,14,16,22-pentaen-7-one
[(1r,2r)-2-hydroxy-6-[(2e,6e,10e)-12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]methyl acetate
(1r,2r,4r,8r,9r,10s,13s,16s)-8-(acetyloxy)-2-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-16-yl acetate
4a,5-dimethyl-2-[(2-methylbutanoyl)oxy]-7-oxo-3-(prop-1-en-2-yl)-octahydronaphthalen-1-yl 2-methylbut-2-enoate
3,4a-dimethyl-6-[(2-methylbut-2-enoyl)oxy]-4-(2-methylpropoxy)-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-5-carboxylic acid
[3-(acetyloxy)-1-[2-(furan-3-yl)ethyl]-6-hydroxy-2,4a-dimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl acetate
(1s,2r,4r,8r,9r,10s,13s,16s)-8-(acetyloxy)-16-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-2-yl acetate
[4-(acetyloxy)-1,2-dimethyl-5-methylidene-1-[2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-2h-naphthalen-4a-yl]methyl acetate
(1r,4r,5as,5br,7as,11as,11br,13r,13as)-1,4,13-trihydroxy-5b,8,8,11a,13a-pentamethyl-1h,4h,5h,5ah,6h,7h,7ah,9h,10h,11h,11bh,12h,13h-chryseno[1,2-c]furan-3-one
6-(acetyloxy)-11-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-3-yl acetate
6-(12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-3-(hydroxymethyl)-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-2-yl acetate
(1r,2r,4r,7s,9r,13r,15s,16s)-16-(acetyloxy)-4,8,8,11,15-pentamethyl-12-oxo-3-oxatetracyclo[11.3.0.0²,⁴.0⁷,⁹]hexadec-10-en-13-yl acetate
(1r,3s,7s,8r,8ar)-8-{2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2s)-2-methyl-3-oxobutanoate
4-{[(2s,3r,4r,4ar,8ar)-4-[2-(furan-3-yl)ethyl]-3-(hydroxymethyl)-4,8,8a-trimethyl-1,2,3,4a,5,6-hexahydronaphthalen-2-yl]oxy}-4-oxobutanoic acid
3-methyl-4-[14-(4-methyl-2,5-dioxofuran-3-yl)tetradecyl]furan-2,5-dione
(3s,4ar,6ar,8s,10r,10ar,10bs)-3-ethenyl-8-hydroxy-3,4a,7,7,10a-pentamethyl-5-oxo-octahydronaphtho[2,1-b]pyran-10-yl (2z)-2-methylbut-2-enoate
(1s,2s,3e,5r,7e,11r)-5-[(2e)-4-hydroxy-4-methylpent-2-en-1-yl]-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
(5s)-4-[(1r,3r,4ar,4bs,6as,10as,10bs,12as)-1-hydroxy-4b,7,7,10a-tetramethyl-tetradecahydrophenanthro[2,1-c]pyran-3-yl]-5-hydroxy-5h-furan-2-one
4-{4,9-dihydroxy-15-methoxy-5-methyl-16-oxapentacyclo[13.2.2.0¹,¹³.0²,¹⁰.0⁵,⁹]nonadecan-6-yl}-5h-furan-2-one
(3r,4as,5r,8s)-4a,5-dimethyl-2-oxo-3-(3-oxoprop-1-en-2-yl)-hexahydro-1ah-naphtho[4,4a-b]oxiren-8-yl decanoate
5-[5-(hydroxymethyl)-5,8a-dimethyl-6-[(2-methylbut-2-enoyl)oxy]-2-methylidene-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-enoic acid
(1s,3r,5r,6as,7r,8r,10as)-1-(acetyloxy)-5-hydroxy-7,8-dimethyl-7-[(2z)-3-methylpenta-2,4-dien-1-yl]-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-3-yl acetate
1-(acetyloxy)-5-hydroxy-7,8-dimethyl-7-(3-methylpenta-2,4-dien-1-yl)-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-3-yl acetate
14-(4,6-dimethoxy-3-oxo-1h-2-benzofuran-1-yl)tetradecane-2,5-dione
(1r)-1-[(1s,4s,6s,10r,11s)-11-(acetyloxy)-4-methyl-9-methylidene-5,12-dioxatricyclo[8.4.0.0⁴,⁶]tetradec-13-en-14-yl]-4-methylpent-3-en-1-yl acetate
(4as,6as,12br,14as,14bs)-10-hydroxy-6a,9,12b,14a-tetramethyl-2-methylidene-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-4a-carbaldehyde
methyl (1s,4ar,6ar,7s,11as,11bs)-1-(acetyloxy)-4a-hydroxy-4,4,7,11b-tetramethyl-1h,2h,3h,5h,6h,6ah,11h,11ah-phenanthro[3,2-b]furan-7-carboxylate
1-hydroxy-1-isopropyl-3a,6-dimethyl-8-[(2-methylbut-2-enoyl)oxy]-2,3,4,7,8,8a-hexahydroazulen-4-yl 2-methylbut-2-enoate
1-methyl 4-[(1s,4r,9r,10s,13s,14r,16s)-5,5,9-trimethyl-15-oxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-13-yl]methyl butanedioate
(5s)-5-[(1e)-2-[(3s,4ar,6s,6as,10as,10br)-6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl]ethenyl]-5-hydroxy-4-methylfuran-2-one
5-[(1r,3as,3bs,4s,5as,7r,9as,9bs,10r,11ar)-3a,4,7,10-tetrahydroxy-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]pyran-2-one
5-[(2z,5e)-7-hydroxy-3-(hydroxymethyl)-7-methyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,5-dien-1-yl]-4-(hydroxymethyl)-5h-furan-2-one
(2r)-2-[(2r)-4-[(3s)-3,7-dimethylocta-1,6-dien-3-yl]-2-(2-methoxyethenyl)-5-oxofuran-2-yl]-2-hydroxyethyl 2-methylbut-2-enoate
2-[(3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
[(4r,4ar,5r,6as,7r,11as,11br)-5-(acetyloxy)-4-(hydroxymethyl)-7,11b-dimethyl-1h,2h,3h,4ah,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-4-yl]methyl acetate
(2e)-5-[(1r,4as,5s,6r,8as)-5-(hydroxymethyl)-5,8a-dimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-methylidene-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-enoic acid
4-methoxy-2-methyl-3,6-dioxo-5-(pentadec-10-en-1-yl)cyclohexa-1,4-dien-1-yl acetate
(2e,6e,10e,14e)-16-{[(2e)-3-carboxyprop-2-enoyl]oxy}-2,6,10,14-tetramethylhexadeca-2,6,10,14-tetraenoic acid
2-[(2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,4s,5r,6r,9s,10r,12s,13s,14r)-6-(acetyloxy)-5-[(acetyloxy)methyl]-9,13-dimethylpentacyclo[11.2.1.0¹,¹⁰.0⁴,⁹.0¹²,¹⁴]hexadecane-5-carboxylic acid
5,7-dimethoxy-3-{6-[(2s,5s,7s)-7-methyl-1,6-dioxaspiro[4.4]nonan-2-yl]hexyl}-3h-2-benzofuran-1-one
4-{1,5-dihydroxy-4-[4-methyl-6-(2,6,6-trimethylcyclohex-1-en-1-yl)hex-3-en-1-yl]pent-3-en-1-yl}-5-hydroxy-5h-furan-2-one
[11-(acetyloxy)-2-hydroxy-5,9-dimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methyl acetate
(1r,4s,6r,9r,10s,11s,13r)-6-(acetyloxy)-13-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
(2s)-2-[(1s,2s,3e,7e,10s)-2-hydroxy-4,8-dimethyl-10-{[(2z)-2-methylbut-2-enoyl]oxy}cyclodeca-3,7-dien-1-yl]propyl (2z)-2-methylbut-2-enoate
(4s,4as,5r,6s,8ar)-3,4a-dimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-4-(2-methylpropoxy)-4h,5h,6h,7h,8h,8ah,9h-naphtho[2,3-b]furan-5-carboxylic acid
4-({4,4,7,8a-tetramethyl-8-[2-(5-oxo-2h-furan-3-yl)ethyl]-1,2,3,4a,5,8-hexahydronaphthalen-2-yl}oxy)-4-oxobutanoic acid
(2r,3r,4s,5s,6r)-2-{[(1r,2s,4as,5s,8s,8ar)-5,8-dihydroxy-2-isopropyl-4a,8-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
6-(acetyloxy)-8-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
methyl 2,4-dihydroxy-5-{[1-(hydroxymethyl)-2,4a-dimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-3-methoxybenzoate
(2s,3r,4s,5s,6r)-2-({2-[(2r,4ar,5s,8r,8ar)-5,8-dihydroxy-4a,8-dimethyl-octahydronaphthalen-2-yl]propan-2-yl}oxy)-6-(hydroxymethyl)oxane-3,4,5-triol
2-{[4-hydroxy-6-(2-hydroxypropan-2-yl)-4,8a-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
7-ethenyl-10-hydroxy-1,4a,8-trimethyl-2-[(3-methylbutanoyl)oxy]-2,3,4,4b,5,6,8a,9,10,10a-decahydrophenanthrene-1-carboxylic acid
5-(5-formyl-1,2-dimethyl-4a-{[(3-methylbut-2-enoyl)oxy]methyl}-2,3,4,7,8,8a-hexahydronaphthalen-1-yl)-3-methylpentanoic acid
(1ar,3r,4as,5r,8s,8as)-4a,5-dimethyl-2-oxo-3-(3-oxoprop-1-en-2-yl)-hexahydro-1ah-naphtho[4,4a-b]oxiren-8-yl decanoate
6-(acetyloxy)-5-[(acetyloxy)methyl]-9,13-dimethylpentacyclo[11.2.1.0¹,¹⁰.0⁴,⁹.0¹²,¹⁴]hexadecane-5-carboxylic acid
5-[(2z)-4-hydroxy-3-[(3e)-6-(3-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl)-4-methylhex-3-en-1-yl]but-2-en-1-yl]-4-(hydroxymethyl)-5h-furan-2-one
(3br,4s,5as,9as,9br,10s)-4-(acetyloxy)-3b,6,6,9a-tetramethyl-1-oxo-3h,4h,5h,5ah,7h,8h,9h,9bh,10h,11h-phenanthro[1,2-c]furan-10-yl acetate
(2s,3r,4s,5s,6r)-2-{[(3r,6e,10s)-3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1r,2s,4ar,6as,7r,11as,11bs)-2-(acetyloxy)-4a-hydroxy-4,4,7,11b-tetramethyl-1h,2h,3h,5h,6h,6ah,7h,11h,11ah-phenanthro[3,2-b]furan-1-yl acetate
(1r,4r,6s,8s,9r,10s,11s,13s)-6-(acetyloxy)-8-hydroxy-5,5,9-trimethyl-14-methylidene-15-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-11-yl acetate
4,16,22-trihydroxy-8-methyl-9,25-dioxabicyclo[22.1.0]pentacosa-2,11,13,17,19-pentaen-10-one
5-hydroxy-4-{1-hydroxy-4b,7,7,10a-tetramethyl-tetradecahydrophenanthro[2,1-c]pyran-3-yl}-5h-furan-2-one
[2-hydroxy-6-(12-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-5-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl]methyl acetate
3-ethenyl-8-hydroxy-3,4a,7,7,10a-pentamethyl-5-oxo-octahydronaphtho[2,1-b]pyran-10-yl 2-methylbut-2-enoate
n-{[(7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl)oxy](hydroxy)methylidene}-2-hydroxyethanecarbamimidic acid
(2e,4e)-n-(2,5-dihydroxy-6-isopropyl-3,7-dimethyl-8-oxo-1,4,7-triazacyclododeca-1,4-dien-9-yl)octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
(1s,4s,5s,6r,9r,10r,13r)-10-hydroxy-5,9,14-trimethyl-6-[(3-methylbutanoyl)oxy]tetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-14-ene-5-carboxylic acid
3-hydroxy-4,7,8a,11,12b,14a-hexamethyl-9,11,12,12a,13,14-hexahydro-8h-picene-2,10-dione
(2r,3r,4s,5s,6r)-2-{[(1s,4s,4as,6s,8as)-4-hydroxy-6-(2-hydroxypropan-2-yl)-4,8a-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(3s)-3-[(2s)-5-{2-[(1as,4ar,5s,6s,8as)-1a,5,6-trimethyl-octahydrocyclopropa[e]naphthalen-5-yl]ethyl}-2-hydroxy-3,6-dihydropyran-2-yl]-4-oxobutanoic acid
(2s)-n-[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-2-[(2r)-2-(methoxycarbonyl)-5-oxopyrrolidin-1-yl]propanimidic acid
1-methyl 4-{5,9,13-trimethyl-15-oxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-5-yl}methyl butanedioate
(3s,4ar,6ar,8s,10r,10ar,10bs)-3-ethenyl-10-hydroxy-3,4a,7,7,10a-pentamethyl-5-oxo-octahydronaphtho[2,1-b]pyran-8-yl (2z)-2-methylbut-2-enoate
2-[(10,11-dihydroxy-3,7,11-trimethyldodeca-1,6-dien-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
(5s)-4-[(3e,7e)-10-[(1s,5r)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
(3s,4r,5s)-3-[13-(2h-1,3-benzodioxol-5-yl)tridecyl]-4-hydroxy-5-methyloxolan-2-one
(2e)-5-[(1r,4as,5s,6r,8ar)-5-(hydroxymethyl)-5,8a-dimethyl-6-{[(2z)-2-methylbut-2-enoyl]oxy}-2-methylidene-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-enoic acid
n-({[(2r,4ar,7r,8as,10as)-7-ethenyl-1,1,4a,7-tetramethyl-3,4,6,8,8a,9,10,10a-octahydro-2h-phenanthren-2-yl]oxy}(hydroxy)methylidene)-2-hydroxyethanecarbamimidic acid
(2s,3r,4s,5s,6r)-2-{[(6e)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
4-[(3r,4ar,4bs,10as,10bs,12as)-1-hydroxy-4b,7,7,10a-tetramethyl-tetradecahydrophenanthro[2,1-c]pyran-3-yl]-5-hydroxy-5h-furan-2-one
10-hydroxy-5,9-dimethyl-15-[(3-methylbutanoyl)oxy]-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
4-methoxy-5-methyl-3,6-dioxo-2-(pentadec-10-en-1-yl)cyclohexa-1,4-dien-1-yl acetate
1-methyl 4-[(1s,4s,5r,9r,10s,13s,14r,16s)-5,9,13-trimethyl-15-oxapentacyclo[11.3.1.0¹,¹⁰.0⁴,⁹.0¹⁴,¹⁶]heptadecan-5-yl]methyl butanedioate
16-{[3-(4-hydroxyphenyl)prop-2-enoyl]oxy}hexadecanoic acid
(3r)-5-[(1s,2r,4as,8ar)-5-formyl-1,2-dimethyl-4a-{[(3-methylbut-2-enoyl)oxy]methyl}-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpentanoic acid
(1s,2r,4ar,4bs,8ar,10r,10ar)-7-ethenyl-10-hydroxy-1,4a,8-trimethyl-2-[(3-methylbutanoyl)oxy]-2,3,4,4b,5,6,8a,9,10,10a-decahydrophenanthrene-1-carboxylic acid
(2s,3r,4s,5s,6s)-2-{[(3r,6e,10s)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(1s,2r,3r,4ar,5s,8as)-4a,5-dimethyl-2-{[(2r)-2-methylbutanoyl]oxy}-7-oxo-3-(prop-1-en-2-yl)-octahydronaphthalen-1-yl (2e)-2-methylbut-2-enoate
(2r,3r,4s,5s,6r)-2-{[(1r,3ar,4r,5r,7as)-1-hydroxy-1-(hydroxymethyl)-5-isopropyl-7a-methyl-hexahydro-2h-inden-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r)-1-(1-{[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-c-hydroxycarbonimidoyl}-1-methylethyl)-5-oxopyrrolidine-2-carboxylic acid
3-{2-[(1s,2r,4ar,8ar)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]ethyl}-5-oxo-2h-furan-2-yl tert-butyl carbonate
4-methoxy-5-methyl-3,6-dioxo-2-[(10z)-pentadec-10-en-1-yl]cyclohexa-1,4-dien-1-yl acetate
(2r)-n-[(5s,6r,7s,10r)-7-isopropyl-2,10-dimethylspiro[4.5]dec-1-en-6-yl]-2-[(2s)-2-(methoxycarbonyl)-5-oxopyrrolidin-1-yl]propanimidic acid
5-(3-hydroxy-4-methylpent-4-en-1-yl)-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
(5r)-4-[(1s,3r,4ar,4bs,6as,10as,10bs,12as)-1-hydroxy-4b,7,7,10a-tetramethyl-tetradecahydrophenanthro[2,1-c]pyran-3-yl]-5-hydroxy-5h-furan-2-one
5-hydroxy-5-(2-{6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl}ethenyl)-4-methylfuran-2-one
(8as,11r,12ar,12bs,14as)-3-hydroxy-4,7,8a,11,12b,14a-hexamethyl-9,11,12,12a,13,14-hexahydro-8h-picene-2,10-dione
3-[(5-{3-[(5-aminopentyl)-c-hydroxycarbonimidoyl]-n-hydroxypropanamido}pentyl)(hydroxy)carbamoyl]propanoic acid
(1r,2r,3z,5s,7e,11s)-5-[(3s)-3-hydroxy-4-methylpent-4-en-1-yl]-8-(hydroxymethyl)-1,5-dimethyl-12-oxabicyclo[9.1.0]dodeca-3,7-dien-2-yl 3-methylbut-2-enoate
4-[(7e)-10-[(1s,5r)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
13-isopropyl-15-[3-methoxy-5-(1h-pyrrol-2-yl)furan-2-yl]-2-azatricyclo[10.2.1.1³,¹⁴]hexadeca-1(15),2,14(16)-triene
(2s,3s,4s,5s,6s)-2-{[(3s,6e,10s)-3,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(5r)-4-[(3e,7e)-10-[(1s,5s)-1-acetyl-5-hydroxy-2,2-dimethylcyclopentyl]-4,8-dimethyldeca-3,7-dien-1-yl]-5-hydroxy-5h-furan-2-one
(1s,4s,5r,9r,10r,13r,15s)-10-hydroxy-5,9-dimethyl-15-[(3-methylbutanoyl)oxy]-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylic acid
(2s,3r,4s,5s,6r)-2-{[(3r,6e,10s)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2s,3r,4s,5s,6s)-2-{[(3s,6e,10s)-2,10-dihydroxy-2,6,10-trimethyldodeca-6,11-dien-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
5-(2-hydroxy-2-{6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl}ethylidene)-4-methylfuran-2-one
(2s,3r,4r,5r,6s)-2-{[(1r,3ar,4r,5r,7as)-1-hydroxy-1-(hydroxymethyl)-5-isopropyl-7a-methyl-hexahydro-2h-inden-4-yl]methoxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2e,4e,6e)-n-[(3s,6s,9s)-2,8-dihydroxy-6-isopropyl-3,4-dimethyl-5-oxo-1,4,7-triazacyclododeca-1,7-dien-9-yl]octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)
5-[(1e)-2-[(3r,4ar,6s,6as,10as,10br)-6-hydroxy-3,4a,7,7,10a-pentamethyl-octahydro-1h-naphtho[2,1-b]pyran-3-yl]ethenyl]-5-hydroxy-4-methylfuran-2-one
(3s,3ar,4s,5ar,7s,9as,11ar)-3,4,7-trihydroxy-1-[(2s)-1-hydroxypropan-2-yl]-3a,6,6,9a,11a-pentamethyl-3h,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-10-one
2-{[4-hydroxy-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
n-(2,5-dihydroxy-6-isopropyl-3,7-dimethyl-8-oxo-1,4,7-triazacyclododeca-1,4-dien-9-yl)octa-2,4,6-trienimidic acid
C22H34N4O4 (418.25799240000003)